ORCID as entered in ROS

Select Publications
2015, 'Quality of Life in Autoimmune Blistering Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 623 - 631, http://dx.doi.org/10.1007/978-3-662-45698-9_67
,2015, 'Rituximab and Its Use in Autoimmune Bullous Disorders', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 523 - 529, http://dx.doi.org/10.1007/978-3-662-45698-9_53
,2015, 'Special Issues in Epidermolysis Bullosa: Eyes, Hair, Nails, Teeth and Pregnancy', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 695 - 709, http://dx.doi.org/10.1007/978-3-662-45698-9_73
,2015, 'Supportive Care: Bathing, Wound Care, Nutrition, Pain and Itch Management, Psychosocial Support, Palliation', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 653 - 666, http://dx.doi.org/10.1007/978-3-662-45698-9_70
,2015, 'Tetracyclines and Their Use in Autoimmune Bullous Diseases and Epidermolysis Bullosa', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 501 - 505, http://dx.doi.org/10.1007/978-3-662-45698-9_50
,2015, 'The Pathogenesis, Assessment and Management of Pruritus in Autoimmune Bullous Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 643 - 649, http://dx.doi.org/10.1007/978-3-662-45698-9_69
,2015, 'The Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 533 - 541, http://dx.doi.org/10.1007/978-3-662-45698-9_54
,2015, 'Treatment and Prevention of Glucocorticoid-Induced Osteoporosis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 593 - 603, http://dx.doi.org/10.1007/978-3-662-45698-9_63
,2015, 'Treatment of Dermatitis Herpetiformis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 573 - 578, http://dx.doi.org/10.1007/978-3-662-45698-9_60
,2015, 'Treatment of EB Complications: Esophageal Strictures, Pseudosyndactyly, Urethral and Meatal Stenosis, and Laryngeal Stenosis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 687 - 694, http://dx.doi.org/10.1007/978-3-662-45698-9_72
,2015, 'Using Intravenous Immunoglobulins in Autoimmune Bullous Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 515 - 521, http://dx.doi.org/10.1007/978-3-662-45698-9_52
,2014, 'Pemphigus', in Evidence Based Dermatology Third Edition, pp. 552 - 560, http://dx.doi.org/10.1002/9781118357606.ch65
,2011, 'Erythema Multiforme, Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis', in Harper's Textbook of Pediatric Dermatology, Wiley, pp. 78.1 - 78.8, http://dx.doi.org/10.1002/9781444345384.ch78
,2011, 'Diagnosis and Prevention of Bullous Diseases', in Preventive Dermatology in Infectious Diseases, Springer London, pp. 53 - 73, http://dx.doi.org/10.1007/978-0-85729-847-8_6
,2009, 'The Cochrane Skin Group', in Evidence Based Dermatology Second Edition, pp. 20 - 25, http://dx.doi.org/10.1002/9781444300161.ch4
,2003, 'Interventions for bullous pemphigoid', in The Cochrane Library, John Wiley & Sons, UK
,2003, 'Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita (Cochrane Review)', in Cochrane Database of Systematic Reviews, John Wiley & Sons Ltd, England
,2003, 'The Cochrane Skin Group', in Williams H; Bigby M; Diepgen T; Herxheimer A; Naldi L; Rzany B (ed.), Evidence-based Dermatology, BMJ Publishing Group, London, UK, pp. 24 - 32
,2025, 'Author Correction: Bullous pemphigoid (Nature Reviews Disease Primers, (2025), 11, 1, (12), 10.1038/s41572-025-00595-5)', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00605-6
,2025, 'Bullous pemphigoid', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00595-5
,2025, 'Colchicine as a treatment option for inherited epidermolysis bullosa', Clinical and Experimental Dermatology, 50, pp. 1238 - 1240, http://dx.doi.org/10.1093/ced/llaf016
,2025, 'Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires', Journal of Dermatology, 52, pp. 812 - 830, http://dx.doi.org/10.1111/1346-8138.17707
,2025, 'Leveraging space innovations for cancer breakthroughs on Earth', Trends in Cancer, 11, pp. 433 - 440, http://dx.doi.org/10.1016/j.trecan.2025.02.003
,2025, 'The development and validation of an investigator global assessment score for keratosis pilaris', Journal of the European Academy of Dermatology and Venereology, 39, pp. e350 - e352, http://dx.doi.org/10.1111/jdv.20326
,2025, 'Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece', Jid Innovations, 5, http://dx.doi.org/10.1016/j.xjidi.2024.100339
,2025, 'Assessment of a Real-Time PCR Assay for the Detection of Dermatophytosis by Sampling With an Adhesive Tape Technique', Australasian Journal of Dermatology, 66, pp. e60 - e61, http://dx.doi.org/10.1111/ajd.14415
,2025, 'Ethics of publication mills and payment for guaranteed authorships', Journal of the American Academy of Dermatology, 92, pp. 666 - 667, http://dx.doi.org/10.1016/j.jaad.2024.10.034
,2025, 'Toward gender equity for all members of the academic dermatology community', Clinics in Dermatology, 43, pp. 248 - 250, http://dx.doi.org/10.1016/j.clindermatol.2025.01.004
,2025, 'Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy', Journal of the European Academy of Dermatology and Venereology, 39, pp. 340 - 349, http://dx.doi.org/10.1111/jdv.20149
,2025, 'Body image disturbance has severe psychosocial impacts in patients suffering from autoimmune blistering diseases', Journal of the European Academy of Dermatology and Venereology, 39, pp. 253 - 254, http://dx.doi.org/10.1111/jdv.20491
,2025, 'Bullous pemphigoid burden of disease, management and unmet therapeutic needs', Journal of the European Academy of Dermatology and Venereology, 39, pp. 290 - 300, http://dx.doi.org/10.1111/jdv.20313
,2025, 'Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External Experts', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17668
,2025, 'Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14532
,2024, 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council', British Journal of Dermatology, 192, pp. 135 - 143, http://dx.doi.org/10.1093/bjd/ljae342
,2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
,2024, 'Digital twins in dermatology, current status, and the road ahead', Npj Digital Medicine, 7, http://dx.doi.org/10.1038/s41746-024-01220-7
,2024, 'Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)', Advances in Therapy, 41, pp. 4418 - 4432, http://dx.doi.org/10.1007/s12325-024-02992-w
,2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, 42, pp. 723 - 726, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
,2024, 'Establishing minimal clinically important differences for the Pemphigus Disease Area Index', British Journal of Dermatology, 191, pp. 823 - 831, http://dx.doi.org/10.1093/bjd/ljae283
,2024, 'Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial', Eclinicalmedicine, 77, http://dx.doi.org/10.1016/j.eclinm.2024.102900
,2024, 'Keratosis pilaris treatment paradigms: Assessing effectiveness across modalities', Clinical and Experimental Dermatology, 49, pp. 1105 - 1117, http://dx.doi.org/10.1093/ced/llae066
,2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, 65, pp. e145 - e155, http://dx.doi.org/10.1111/ajd.14308
,2024, 'Dermatology Journal Advisory Boards and editorial independence', Jaad International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001
,2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002
,2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023
,2024, 'Gender equity in academic dermatology: Problems aplenty, yet paths ahead', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1504 - 1513, http://dx.doi.org/10.1111/jdv.20027
,2024, 'Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT (Advances in Therapy, (2024), 41, 7, (2991-3002), 10.1007/s12325-024-02810-3)', Advances in Therapy, 41, pp. 3014 - 3015, http://dx.doi.org/10.1007/s12325-024-02886-x
,2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1006 - 1023, http://dx.doi.org/10.1111/jdv.19880
,2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882
,2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038
,